Thr386
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr386  -  SHC1 (human)

Site Information
PTAPNAQtPSHLGAT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 457351

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 )
Disease tissue studied:
adrenal cancer ( 3 ) , pheochromocytoma ( 3 )
Relevant cell line - cell type - tissue:
HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , MEF (fibroblast) [SHC1 (human)] ( 3 ) , PC-12 (chromaffin) ( 3 )

Upstream Regulation
Kinases, in vitro:
P38A (human) ( 3 )
Treatments:
SB203580 ( 3 )

Downstream Regulation
Effects of modification on SHC1:
protein stabilization ( 3 )
Effects of modification on biological processes:
apoptosis, induced ( 3 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Possemato A (2010) CST Curation Set: 9438; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

3

Khanday FA, et al. (2006) Rac1 leads to phosphorylation-dependent increase in stability of the p66shc adaptor protein: role in Rac1-induced oxidative stress. Mol Biol Cell 17, 122-9
16251354   Curated Info